Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

30.48 +0.33 (+1.08%)
Streaming Delayed Price Updated: 11:00 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Was Victorious This Week ↗
Via The Motley Fool
News headline image
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday ↗
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors. 
Via The Motley Fool
Topics World Trade
News headline image
Is Novo Nordisk Stock a Buy? ↗
Via The Motley Fool
News headline image
Earnings Scheduled For April 23, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For Viking Therapeutics ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Viking Therapeutics? ↗
 
Via Benzinga
News headline image
Where Will Viking Therapeutics Be in 3 Years? ↗
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years. 
Via The Motley Fool
Topics Bankruptcy
News headline image
1 Beaten-Down Stock to Buy and Hold for 10 Years ↗
Via The Motley Fool
Topics Economy
News headline image
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? ↗
Via The Motley Fool
News headline image
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Popped Again Today ↗
Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Popped Today ↗
2025 is the year we learn whether Viking Therapeutics stock will be a winner. 
Via The Motley Fool
News headline image
Viking Therapeutics Stock May Struggle After As-Expected Report
Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard. 
Via MarketBeat
News headline image
Viking Therapeutics Stock Dips After Q1 EPS Miss: Details ↗
Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the report. 
Via Benzinga
News headline image
A Look At Viking Therapeutics VKTX ↗
While we wait for the earnings report to be posted along with the forward guidance predictions, the chart looks interesting. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Did Eli Lilly Just Say Checkmate to Novo Nordisk? ↗
Via The Motley Fool
News headline image
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide ↗
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
News headline image
2 Stocks Down by 25% or More This Year to Buy and Hold ↗
Via The Motley Fool
Topics Government
News headline image
Eli Lilly Stock Rockets On Weight-Loss Pill Progress ↗
Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles. 
Via Investor's Business Daily
Topics Government
News headline image
Viking Therapeutics Stock Pops But Struggles to Hold Gains
VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington 
Via MarketBeat
News headline image
Will Pfizer Approach Viking Therapeutics With A Buyout Proposa ↗
Investors are running into Viking Therapeutics this week after an incident of drug-induced liver injury pushed Pfizer into terminating the development of its weight-loss pill. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock? ↗
Via The Motley Fool
News headline image
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish ↗
Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates. 
Via Stocktwits
News headline image
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today ↗
Pfizer bows, but is not entirely out of the GLP-1 race. 
Via The Motley Fool
News headline image
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
News headline image
Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury ↗
The company is continuing to test a daily pill that blocks GIPR. 
Via Investor's Business Daily
News headline image
3 Magnificent Stocks That Could Double or More by 2030 ↗
Via The Motley Fool
News headline image
Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years? ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.